|
|
||||||||||
|
J Am Coll Cardiol, 2001; 38:1614-1621 © 2001 by the American College of Cardiology Foundation |




* Cardiovascular Data Analysis Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan, USA
|| Mid Carolina Cardiology, Charlotte, North Carolina, USA
¶ LeBauer Health Care, Greensboro, North Carolina, USA
# Institut Cardiovasculaire Paris Sud, Antony, France
** Lenox Hill Hospital, New York, New York, USA
Manuscript received March 7, 2001; revised manuscript received July 13, 2001, accepted August 9, 2001.
* Reprint requests and correspondence: Dr. David J. Cohen, Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215 USA
djc{at}hsph.harvard.edu
OBJECTIVES
The goal of this study was to compare the impact of primary stenting or percutaneous transluminal coronary angioplasty (PTCA) on health-related quality of life (HRQOL) in patients undergoing direct angioplasty for acute myocardial infarction (AMI).
BACKGROUND
Previous studies have demonstrated that coronary stenting reduces clinical and angiographic restenosis compared with PTCA. However, the impact of stenting on HRQOL from the patients perspective remains unknown.
METHODS
We administered the Seattle Angina Questionnaire and the Medical Outcomes Study Short-form Survey at 1, 6 and 12 months after initial treatment to all North American patients in the Stent-Primary Angioplasty for Myocardial Infarction trial (Stent-PAMI) (n = 509)a randomized trial comparing primary stenting to conventional PTCA for patients with AMI.
RESULTS
At one month, most HRQOL measures were similar for the two groups, but stent patients reported less bodily pain than PTCA patients (p = 0.03). At six-month follow-up, stenting resulted in significant improvements in several dimensions of HRQOL including reduced anginal frequency and bodily pain as well as improved disease perception (all p
0.03) and a trend towards better anginal stability (p = 0.056). By 12-month follow-up, however, none of these differences remained statistically significant. These differences in HRQOL were largely explained by the greater need for ischemia-driven target-vessel repeat revascularization procedures in PTCA patients during the first six months (16.0% vs. 6.2%, p < 0.001).
CONCLUSIONS
In patients undergoing revascularization for AMI, initial stent placement is associated with improvements in several dimensions of health status during the first six months of follow-up. In the absence of differences in mortality, these findings add to the overall argument in favor of initial stenting in patients treated with mechanical reperfusion for myocardial infarction.
| ||||||||||||||||||||||||||||||
This article has been cited by other articles:
![]() |
J. Ryan and D. J. Cohen Are Drug-Eluting Stents Cost-Effective?: It Depends on Whom You Ask Circulation, October 17, 2006; 114(16): 1736 - 1744. [Full Text] [PDF] |
||||
![]() |
A. Bakhai, G. W. Stone, E. Mahoney, T. A. Lavelle, C. Shi, R. H. Berezin, B. J. Lahue, M. A. Clark, M. J. Lacey, M. E. Russell, et al. Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization: Results From the TAXUS-IV Trial J. Am. Coll. Cardiol., July 18, 2006; 48(2): 253 - 261. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kim, R. A. Henderson, S. J. Pocock, T. Clayton, M. J. Sculpher, K. A.A. Fox, and RITA-3 Trial Investigators Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: One-year results of the third randomized intervention trial of unstable angina (RITA-3) J. Am. Coll. Cardiol., January 18, 2005; 45(2): 221 - 228. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Kernis, K. J. Harjai, G. W. Stone, L. L. Grines, J. A. Boura, W. W. O'Neill, and C. L. Grines Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1773 - 1779. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Greenberg, A. Bakhai, and D. J. Cohen Can we afford to eliminate restenosis?: Can we afford not to? J. Am. Coll. Cardiol., February 18, 2004; 43(4): 513 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, E. M. Mahoney, R. H. Stables, J. Booth, F. Nugara, J. A. Spertus, and W. S. Weintraub Disease-Specific Health Status After Stent-Assisted Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery: One-Year Results From the Stent or Surgery Trial Circulation, October 7, 2003; 108(14): 1694 - 1700. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Cohen, R. S. Cosgrove, R. H. Berezin, P. S. Teirstein, M. B. Leon, R. E. Kuntz, and on behalf of the Gamma-1 Investigators Cost-Effectiveness of Gamma Radiation for Treatment of In-Stent Restenosis: Results From the Gamma-1 Trial Circulation, August 6, 2002; 106(6): 691 - 697. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |